Phase III results show Roche's subcutaneous formulation of Tecentriq is comparable to intravenous Tecentriq and delivered in minutes
Administered under the skin, the subcutaneous formulation reduces time spent receiving treatment to approx. seven minutes, compared with 30-60 minutes for IV infusion1Roche has submitted data from the IMscin001 study to health authorities, seeking approval for the subcutaneous option across all approved indications of IVTecentriq  If approved,Tecentriq would be Roche ’s fourth subcutaneous cancer therapy,2-4 helping to improve the treatment experience for patients. In addition, it could save resources for healthcare systems5-10Basel, 1 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new pivotal data ...
Source: Roche Investor Update - December 1, 2022 Category: Pharmaceuticals Source Type: news

Robotic Resection Cuts Perioperative Morbidity With Liver Cancer
MONDAY, Nov. 28, 2022 -- Robotic liver resection (RLR) is associated with a significant reduction in perioperative morbidity for treatment of hepatocellular carcinoma (HCC) versus open-liver resection (OLR), according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 28, 2022 Category: Pharmaceuticals Source Type: news

Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Radiotherapy Improves Survival in Difficult Liver Cancer Cases Radiotherapy Improves Survival in Difficult Liver Cancer Cases
Stereotactic body radiotherapy plus sorafenib led to a strong survival benefit vs sorafenib alone in advanced hepatocellular carcinoma.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 31, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA approves tremelimumab in combination with durvalumab for unresectable hepatocellular carcinoma
On October 21, 2022, the Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (uHCC). ​​​​​​​ (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 24, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Imjudo (tremelimumab) in Combination with Imfinzi for Patients with Unresectable Hepatocellular Carcinoma
24 October 2022 -- AstraZeneca’s Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 24, 2022 Category: Drugs & Pharmacology Source Type: news

Antiviral Therapy Improves Survival After Liver Cancer Surgery Antiviral Therapy Improves Survival After Liver Cancer Surgery
The analysis focused on elderly patients after hepatectomy for hepatitis B virus –related hepatocellular carcinoma. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 20, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

HCC 10+ Years After Viral Eradication in Patients With HCV HCC 10+ Years After Viral Eradication in Patients With HCV
What risk factors are associated with hepatocellular carcinoma development 10 years or more after SVR?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 7, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Liver Cancer Risk May Rise for 2nd - , 3rd - Generation U.S. Mexicans
Risk of hepatocellular carcinoma increased by 35 and 61 percent for second - , third - versus first - generation U.S. Mexicans (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 20, 2022 Category: Cancer & Oncology Tags: Gastroenterology, Internal Medicine, Oncology, Conference News, Source Type: news

Liver Cancer Risk May Rise for 2nd-, 3rd-Generation U.S. Mexicans
TUESDAY, Sept. 20, 2022 -- The risk of hepatocellular carcinoma (HCC) appears to be increased for successive generations of U.S. Mexicans, according to a study presented at the 15th AACR Conference on the Science of Cancer Health Disparities in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2022 Category: Pharmaceuticals Source Type: news

NAFLD Fibrosis Scores Predict Liver-related HCV Complications NAFLD Fibrosis Scores Predict Liver-related HCV Complications
This study evaluated the use of noninvasive fibrosis assessments for predicting liver-related complications and hepatocellular carcinoma occurrence in patients with chronic HCV receiving DAA therapy.Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 20, 2022 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Novel Blood Test for Early-Stage Liver Cancer Shows Promise Novel Blood Test for Early-Stage Liver Cancer Shows Promise
The blood test identifies early-stage hepatocellular carcinoma in patients at risk with around 90% accuracy and could augment current surveillance methods and improve patient outcomes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 8, 2022 Category: Cancer & Oncology Tags: Gastroenterology News Source Type: news

SGLT2 Inhibitors Lower NAFLD, HCC Risks Over DPP4i SGLT2 Inhibitors Lower NAFLD, HCC Risks Over DPP4i
Sodium glucose cotransporter 2 inhibitors (SGLT2is) lowered the risk of nonalcoholic fatty liver disease and hapatocellular carcinoma versus dipeptidyl-peptidase-4 inhibitors (DPP4is).First Look (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 1, 2022 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Intermediate-Stage HCC Treatment in the Era of Immunotherapy Intermediate-Stage HCC Treatment in the Era of Immunotherapy
Learn more about the therapeutic advances that have redefined the treatment possibilities for intermediate-stage hepatocellular carcinoma.Journal of Oncology Practice (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 1, 2022 Category: Surgery Tags: Hematology-Oncology Journal Article Source Type: news

U.S. FDA Approves IMBRUVICA ® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
August 24, 2022 (HORSHAM, PA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy. This milestone marks the first pediatric indication for IMBRUVICA® and the introduction of a new oral suspension formulation for patients ages one to less than 12. IMBRUVICA® is now the first FDA-approved therapy for these younger patients who previously had no approv...
Source: Johnson and Johnson - August 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news